Offidani, Massimo <br/><br/>
High-dose daunorubicin as liposomal compound (Daunoxome) in elderly patients with acute lymphoblastic leukemia.  [electronic resource] 

 -  The hematology journal : the official journal of the European Haematology Association  2003 
 - 47-53 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study 
<br/><br/><label>ISSN: </label>1466-4860 
<br/><br/><label>Standard No.: </label>10.1038/sj.thj.6200222  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Betamethasone--administration & dosage<br/>Bone Marrow Diseases--chemically induced<br/>Burkitt Lymphoma--drug therapy<br/>Comorbidity<br/>Cyclophosphamide--administration & dosage<br/>Cytarabine--administration & dosage<br/>Daunorubicin--administration & dosage<br/>Disease-Free Survival<br/>Drug Carriers<br/>Female<br/>Follow-Up Studies<br/>Granulocyte Colony-Stimulating Factor--therapeutic use<br/>Humans<br/>Infections--etiology<br/>Leukemia, T-Cell--drug therapy<br/>Life Tables<br/>Liposomes<br/>Male<br/>Methotrexate--administration & dosage<br/>Middle Aged<br/>Precursor B-Cell Lymphoblastic Leukemia-Lymphoma--drug therapy<br/>Prospective Studies<br/>Remission Induction<br/>Safety<br/>Survival Analysis<br/>Topotecan--administration & dosage<br/>Treatment Outcome